Spirometry and fl ow-volume curves Forced expiratory volumes (FEV1 and FVC6) and capacity (FVC)
shows the three common spirometric patterns:
• normal FEV1, normal FVC, normal FEV1/FVC ratio = Normal • low FEV1, normal or low FVC, low FEV1/FVC = Obstructive • low FEV1, low FVC, normal or high FEV1/ FVC = Restrictive Good instruction by the operator and good performance by the subject are vital. The mantra is F-F-F: Full inspiration -Forceful expiration -Full expiration.
In chronic obstructive pulmonary disease (COPD), the true FVC, in terms of an end-plateau (fi gure 1) is often not reached because patients cannot sustain the effort required to reach full expiration (RV), and a slow expired or inspired vital capacity (VC) may exceed the FVC. Because of the time dependency of FVC in COPD, there have been proposals [1] to standardise the FVC at 6 s (FVC6; fi gure 1), and this may have some advantage in "fi eld" or primary care settings. But FVC6, more than FVC, underestimates the true VC and overestimates FEV1/FVC (by 40% versus 35% in fi gure 1), so the notion that FVC6 will replace FVC remains controversial [1] . Anyway, there is an acceptable alternative, in the laboratory setting, for the FVC, which involves a separate measurement of the VC, giving an FEV1/VC ratio.
Maximum effort expiratory fl ow-volume curves
Spirometry plots volume against time; maximum effort expiratory fl ow-volume (MEFV) curves plot the same data as fl ow versus volume (fi gure 2). Various indices can be derived -forced expiratory fl ow at 25, 50 or 75% of FVC or maximum mid-expiratory fl ow over 25-75% of expired FVC; however, they are of limited usefulness because normal variation is so wide. Inspection of the shape of the curve is more pertinent. Airfl ow obstruction shows curvature or scooping of the MEFV curve over the last 50% of FVC; the curve is straight in normal patients (fi gure 2) and slightly scooped in the elderly. When the FEV1/FVC ratio is borderline, the shape of the MEFV curve may or may not support a diagnosis of airfl ow obstruction; repeat testing after a bronchodilator challenge is usually indicated.
Upper airway (extrathoracic) airfl ow obstruction
Obstruction of the upper airway occurs in:
• the larynx and extrathoracic trachea • the pharynx in obstructive sleep apnoea (OSA) The obstruction may be fi xed (present all the time, and affecting inspiration and expiration) or variable. OSA is caused by variable closure (or extreme narrowing) of the pharynx, occurring only during sleep and made worse by obesity of the neck, sleeping supine and alcohol ingestion before retiring.
Narrowing of the pharynx or larynx during wakefulness may be diffi cult to detect with expiratory tests (FEV1) when the structures are "fl oppy". The best test is the maximum inspiratory effort fl ow volume (MIFV) curve where fl ows are greatly reduced at mid-lung volume compared with fl ows on the MEFV curve. The maximal expiratory fl ow at 50% FVC (MEF50)/maximal inspiratory fl ow at 50% FVC (MIF50) ratio is >1.0 (normal <0.8), and the MIFV curve has a characteristic 
Figure 2
MEFV curves plotted against forced expired volume. a) Effect of ageing with a "knee" in young and curvilinearity or scooping (not as severe as in COPD) in older subjects. The FEV1/FVC ratios were 78% and 69% for patients aged 36 and 70 years, respectively. b) The progression of COPD from the early to late stages. Reproduced from truncated shape (fi gure 3b). If the extrathoracic obstruction is fi xed, the MEFV curve will also show truncation of fl ows, especially peak expiratory fl ow (PEF; fi gure 3a). FEV1 is less affected and the Empey index (FEV1 mL/PEF L per min) is >8-10 [2] . Visual inspection of the whole fl owvolume curve is more important than relying on the calculation of fl ow indices.
Bronchodilator response
Any patient on a fi rst visit who has airfl ow obstruction (reduced FEV1/FVC and/or scooping on the MEFV curve) warrants a bronchodilator challenge from a metered dose inhaler or from a nebuliser driven by compressed air. Salbutamol, a  2 agonist, is the usual agent. It is important that bronchodilator medication has been withdrawn for 6 h (short-acting) or 36 h (long-acting) beforehand. There are various ways to express the response.
3) is probably the most reliable index (see [3] ). In COPD patients, 2) overestimates and 4) underestimates the number of responders compared with 3) [4] .
Bronchoconstrictor challenge
PFTs in asthma may be normal; however bronchial hyperresponsiveness to constrictor-provoking agents such as methacholine or mannitol confi rms the diagnosis. FEV1 is the usual measurement; for children, a PEF meter is the usual monitor when exercise is used to induce post-exercise bronchoconstriction, but pocket spirometers that measure FEV1 accurately are now available. For a methacholine challenge, increasing doses are nebulised or given via a dosimeter. The provocative concentration causing a 20% fall in FEV1 (PC20) is the end-point. A PC20 of 16 mg per mL is normal and a PC20 ≤1.0 mg per mL is diagnostic of asthma.
Mannitol is increasing in popularity for bronchial challenges. It is delivered as a dry powder via an inhaler in doubling doses 5-160 mg. A positive test is defi ned as a fall in FEV1 of 15% compared with baseline with a cumulative dose of ≤635 mg Mannitol. Reactivity to Mannitol correlates with other osmotic stimuli as hypertonic saline [5] . Mannitol induces bronchoconstriction by changing the osmolality of the epithelium of the upper respiratory tract which, via mast cell activation, directly or refl exly, induces bronchoconstriction of the smaller intrapulmonary airways.
Reference values
A test result is normal if it falls within the range predicted for the age, sex and height of the patient, based on large population studies of healthy neversmoking adults. Additional factors such as body mass index and habitual activity (fi tness) do not contribute signifi cantly to the mean value or the variance. The scatter of values from a healthy population has a normal (or Gaussian) distribution; in linear regression (e.g. FEV1 versus age) the distribution (or variance) is described by the relative standard deviation (RSD) which is the SD/mean value (also called the coeffi cient of variation). The normal range of values is defi ned arbitrarily as the 90% closest to the mean (the 90% confi dence interval) and this spread is described by the mean±1.645 RSD. 5% of a normal population will fall above and 5% below this cut-off. For example, the actual FEV1 (2.0 L) minus the predicted FEV1 (2.5 L)/1 RSD (0.25) = -2.0 RSD from the predicted mean, and this is referred to as the standardised residual (SR). From 0 to -1.645 SR is normal, -1.645 SR is the lower limit of normal (LLN), from -1.645 to -2.5 SR represents mild deviation from normality, and from -2.5 to -3.5 SR moderate deviation; beyond -3.5 SR represents severe deviation from normality.
120% and 80% of the predicted normal value are approximately equal to ±1.645 SRs. % pred quantifi es the abnormality but does not give the probability that the result is normal; SRs express quantity and probability, and have scientifi c validity. The Pulmonary Function Report should give the absolute value, the SR and the % pred. The % pred is still a useful number as it has an intuitive quantifi able feel.
Ratios (FEV1/FVC, RV/TLC and TL,CO/VA (KCO)) are mostly independent of sex and height, but remain dependent on age. An FEV1/FVC ratio ≤70% is often regarded as abnormal, but the LLN (-1.645 SR) at age ≥60 years is ≤70% for males and females [6] .
Lung volumes
TLC is the maximum achievable lung volume and RV is the minimum. The volume at the end of a relaxed tidal breath at rest is the functional residual capacity (FRC). In restrictive lung disease, caused by intrapulmonary fi brosis, TLC, FRC and RV are reduced equally as a percentage of their predicted values (fi gure 4). In extrapulmonary disease with neuromuscular pathology, TLC is low, but FRC and RV (especially) are relatively well preserved; RV may be increased in mixed inspiratory and expiratory weakness [7] .
In obstructive disease, RV rises fi rst, followed by FRC. In severe emphysema, often with large bullae, TLC increases. The rise of FRC is termed hyperinfl ation; elevation of FRC increases expiratory fl ow rates during tidal breathing, and on exercise, but at the expense of an increase in the elastic work of breathing. FRC and RV increase with normal ageing due to a loss of lung elasticity. The increase of RV in obstructive disease is due to several factors: a) loss of lung elasticity (emphysema), b) bronchoconstriction ± bronchiolar closure and mucus impaction (asthma), and c) airway narrowing and/or obliteration from bronchial and bronchiolar wall pathology (COPD and obliterative bronchiolitis). A summary of lung volume changes is given in fi gure 4.
RV/TLC is a useful index, but only if TLC is normal. In mixed obstructive and restrictive disease (e.g. a smoker with COPD who develops interstitial lung disease with fi brosis), the FEV1/FVC ratio and the MEFV curve will detect the obstructive element better than the RV/TLC ratio. A rise in RV is an early sign of airfl ow obstruction, but it is no more sensitive than the FEV1/FVC ratio.
The gold standard for restrictive lung disease (small lungs) is a TLC <LLN. It is tempting to label a patient "restrictive" when they have a normal or high FEV1/FVC ratio and FVC <LLN (<-1.645 SR) on the basis that all volumes are equally reduced (fi gure 4). But, for 95% certainty the FVC must be <60% of LLN or <50% pred normal [8] . FVC >100% pred excludes restriction.
TL,CO and KCO
(Note that in North America and Australasia, the term DL,CO (diffusing capacity) is used instead of TL,CO).
For interpretation, the vital point to grasp [9, 10] is:
(KCO x VA)/ Pb* = TL,CO (1) TL,CO/VA = kCO/Pb* = KCO (2) where kCO (min -1 or s -1 ) is the rate of uptake of CO from the alveoli (to combine with haemoglobin (Hb) in the pulmonary capillaries) during a 10 s breath-hold at full infl ation (TLC); KCO is a rate constant (or an effi ciency index). VA is the alveolar volume "seen" by CO during the breath hold; VA is 91±8% (1.645 SRs) of TLC [11] , but will be signifi cantly less than this in the presence of airfl ow obstruction, because of gas mixing delays during the short breath hold time. Pb* (barometric pressure minus water vapour pressure at 37˚C) normalises the uptake (mmol or mL per min) per unit pressure (kPa or mmHg), so that the product, TL,CO, has units of conductance, mmol per min per kPa in SI units (mL per min per mmHg in traditional units); divide by three to convert traditional to SI. The KCO is the rate constant normalised to Pb, but the clumsy units used in pulmonary function reports (mmol per min per kPa per L) give the misleading impression that the rate constant KCO corrects TL,CO for lung volume. It does not; in normal subjects the relationship between TL,CO and VA is not linear.
Once the physiology has been grasped (equations 1 and 2), the meaning of a low TL,CO depends on the relationship between its components, KCO and VA. The causes of a low and high KCO are given in table 1.
A low KCO is caused by microvascular disease with or without diffuse alveolar damage. Anaemia (and a high carboxyhaemoglobin from smoking) reduce the KCO, however, corrections can be made, and patients should be asked not to smoke for 12-24 h before testing. Paradoxically, physiological factors are the reason for a high KCO (> pred KCO at the pred TLC) in most instances. Reduced alveolar expansion (the breath-hold is at less than the pred TLC) elevates KCO because the capillary (and Hb) to alveolar volume ratio increases. KCO rises with exercise because high blood fl ow increases pulmonary capillary volume; KCO increases with a left-to-right intracardiac shunt for 
Figure 4 Typical lung volume changes in obstructive and restrictive patterns and in ageing patients. In ageing patients, RV increases and VC decreases by an equal amount, and the same occurs with FRC increasing and inspiratory capacity (IC

Table 1 Some causes and some examples of low and high KCO
the same reason. KCO increases following a pneumonectomy (from 98 to 111% pred [12] ) because blood fl ow per unit volume approximately doubles. It follows that loss of aerated lung units from any cause will divert blood fl ow to the remaining units, provided they are structurally sound, increasing their blood fl ow per unit volume. This is called discrete loss of units (table 1) . The causes of a low VA -1) reduced expansion, 2) discrete loss of units, 3) diffuse alveolar damage (fi brosis) and 4) poor gas mixing (airfl ow obstruction) -are associated with different values of KCO. Therefore, the interpretation of a TL,CO of, say, 60% pred depends critically on the relationships between the KCO and VA components (table 2), each of which has a different pathological connotation [9] .
A normal KCO, accompanying a low TL,CO, has physiological meaning; it should not be regarded as an artefact. It indicates "mixed" disease, e.g. a mixture (from table 2) of lack of alveolar expansion or "discrete"loss of units with alveolar-capillary or microvascular damage -alveolar consolidation plus fi brosis in chronic interstitial lung disease, for example.
The combination of spirometry, lung volumes (as TLC) and TL,CO and KCO is shown in an algorithm in fi gure 5, which starts with the FEV1/FVC ratio (normal or low) and divides sequentially on the basis of a normal or low FVC and TLC, a low or normal TL,CO and a high, normal or low KCO [13] .
Respiratory muscle function
All pulmonary function laboratories should be able to measure the maximum pressures the inspiratory muscles can develop at RV or FRC (PI,max) and those the expiratory muscles can produce at TLC (PE,max). These are static pressures (fl ow is absent or minimal) and the glottis must remain open (with PI,max a small leak is introduced) so that alveolar pressure is recorded. The tests are essentially Mueller (PI,max) and Valsalva (PE,max) manoeuvres. Peak pressures should be sustained for 3 s. Flanged mouthpieces are preferred. Patients with facial weakness may have problems. Even so, many patients and normal subjects fi nd it diffi cult to produce a maximal effort, although dynamic manoeuvres involving maximum efforts (FEV1, MEFV and MIFV curves) are in general performed very well. Thus, many patients underperform; 30% of patients with low PI,max or PE,max are normal after further testing. Sniffi ng (sniff Pnasal) [14] , coughing (cough
Interpretation of pulmonary function tests
Pgastric) [15] and blowing a whistle (Pmouth, whistle) [16] are more natural and more familiar ways of obtaining an estimate of respiratory muscle capacity, except that they test force-velocity as well as force-pressure relationships. However, in the future, they should be introduced into all laboratories alongside the static PI,max and PE,max tests, as there is a good correlation between the dynamic (sniffs, etc.) and static manoeuvres.
For PI,max and PE,max, the lower limit of normal is set at -1.96 SRs (95% confi dence limits) rather than -1.645 because submaximal performance is common [17] . PI,max and PE,max are lower in females and decline with age. As a screen for respiratory muscle weakness, PI,max should be less than (more negative=stronger) -45 cmH 2 O for males and <-30 cmH 2 O for females. PE,max should be >80 cmH 2 O in males and >60 cmH 2 O in females [15] . Nasal pressures during a sniff exceed the LLN for PI,max by 15% in males and by 40% in females. Cough gastric pressures for males and females are 50% higher compared with PE,max [15] . Whistle mouth pressures are higher than PE,max but lower than cough gastric pressures [16] .
If respiratory pressures are low, patients will usually be referred to more specialised centres for further tests such as maximum transdiaphragmatic pressure or magnetic stimulation of the phrenic nerve roots (over the cervical spinal cord) or of individual phrenic nerves in the neck if unilateral diaphragm paralysis is suspected.
A high KCO (>120% predicted) and a restrictive spirometric and volume pattern should alert the laboratory to the possibility of neuromuscular weakness, and prompt a measurement of PI,max and PE,max.
Exercise
Exercise testing is used most frequently as a performance indicator. Less emphasis is placed now on its role in physiological diagnosis. However, two questions may be asked: 1) is this patient's exertional dyspnoea due to cardiac and/or pulmonary disease; and 2) is cardiac or is pulmonary disease contributing more to this patient's exercise intolerance?
Exertional dyspnoea accompanied by a normal pulmonary function screen may be caused by:
• anaemia • cardiovascular disease: i) left ventricular (LV) dysfunction; ii) pulmonary vascular disease • anxiety (psychogenic breathlessness)
It is easy to exclude anaemia. Ischaemic heart disease (LV dysfunction) is usually accompanied by chest pain or ST-segment abnormalities on the exercise electrocardiogram. Pulmonary vascular disease usually shows some reduction of TL,CO and KCO, and exercise capacity is limited very early by extreme dyspnoea and faintness. In contrast, psychogenic breathlessness is more pronounced at rest, with an irregular chaotic breathing pattern and a low alveolar carbon dioxide tension and bicarbonate. These patients perform normally on exercise with normal parameters, though they may not reach their predicted maximum.
The second question concerning a cardiac or pulmonary origin of exertional dyspnoea requires full cardiopulmonary exercise testing with measurements of gas exchange and minute ventilation (V'E; oxygen uptake (V'O 2 ), carbon dioxide production (V´CO 2 ) respiratory exchange ratio, dead space volume (VD)/tidal volume (VT)) and calculation of the anaerobic threshold (AT). Chronic heart failure is characterised by an AT occurring at a low V'O 2 (<30% of pred maximal V'O 2 ) with a high VD/ VT ratio; maximum pred heart rate occurs at a low V'O 2 (there is no heart rate reserve (HRR) at the end-point). In COPD, the AT is often not achieved because of ventilatory limitation, nor is the maximum pred heart rate reached (there is surplus HRR at the breaking point). Maximum exercise V'E exceeds the predicted maximum voluntary ventilation (~FEV1 (actual) × 40) in COPD, but in heart failure maximal V'E is <FEV1 × 40.
Figure 5
Usual spirometric, lung volume and transfer factor (TL,CO and KCO) patterns for common pulmonary disorders. PVD: pulmonary vascular disease; CW: chest wall; NMD: neuromuscular disease; ILD: interstitial lung disease. Reproduced from 
Tests for small airways disease
Small or peripheral airways are usually defi ned as airways <2 mM diameter. In fact, almost all intrapulmonary airways are <2 mM in diameter and most of those (in terms of numbers and area) are bronchioles (≤0.8 mM diameter). The bronchioles are an important site of pathology in COPD, in asthma, in the bronchiolectasis of cystic fi brosis, and in post-transplant obstructive disease (~bronchiolitis obliterans). The standard pulmonary func-tion tests (FEV1, MEFV curves, airway resistance or specifi c conductance) refl ect the narrowing of all intrathoracic airways. What PFTs are specifi c for the bronchioles? The most sensitive and specifi c test is the multi-breath nitrogen wash-out analysis of VERBANCK et al. [17] with calculation of Scond and Sacin, where S refers to the slopes of the alveolar plateau for expired nitrogen for individual breaths. For further discussion of this and other "bronchiolar" tests, see [18] . A simpler test of uneven ventilation, the phase III slope of the single-breath nitrogen test may also be a good, if less specifi c, marker of bronchiolar abnormalities.
